CD274 and non-small cell lung carcinoma: After these studies, Grizzi et al. [177] reported their preliminary data analysis on 27 NSCLC patients, stage IV or IIIB and ineligible for local therapy, treated with monoclonal IgG targeting PD-1 or PD-L1 as single agent (54 patients with nivolumab, 21 with pembrolizumab, and 5 with atezolizumab, respectively).